NCT04758962View on ClinicalTrials.gov

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

June 4, 2021

Study Completion Date

April 19, 2022

Conditions
Virus Diseases
Interventions
BIOLOGICAL

1 µg CoV2 SAM (LNP)

2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.

Trial Locations (1)

14609

GSK Investigational Site, Rochester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04758962 - A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults | Biotech Hunter | Biotech Hunter